Cartesian Therapeutics (RNAC)

Executive Summary

Cartesian Therapeutics is a clinical-stage biotechnology company pioneering a novel class of mRNA-engineered cell therapies for autoimmune diseases. Its lead product, Descartes-08, is a transiently modified autologous mRNA CAR-T therapy targeting B-cell maturation antigen (BCMA) and designed to provide a safer, more controllable alternative to traditional CAR-T therapies. Descartes-08 is currently in a Phase 3 clinical trial for generalized myasthenia gravis (MG), with additional Phase 2 trials ongoing for systemic lupus erythematosus (SLE), antisynthetase syndrome, and other autoimmune indications. The company’s platform leverages mRNA electroporation to transiently express the CAR, avoiding the risks of genomic integration and allowing for repeat dosing. Cartesian believes this approach could enable safer and more scalable cell therapies for large autoimmune patient populations. The company’s pipeline also includes earlier-stage programs in oncology, though the focus has shifted to autoimmune diseases following promising Phase 2 data in MG. With multiple clinical readouts expected in 2026-2027, Cartesian represents a high-upside opportunity in the emerging field of mRNA cell therapies for autoimmunity, though execution risks remain given the early stage of the platform.

Upcoming Catalysts (preview)

• Q2 2026Descartes-08 Phase 2b topline data in generalized myasthenia gravis60% success
• Q4 2026Descartes-08 Phase 2 interim or final data in systemic lupus erythematosus (SLE)50% success
• Q3 2026Descartes-08 Phase 2 data in antisynthetase syndrome45% success